Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone

Journal of the National Cancer Institute

Volumn 90, Issue 2, 1998, Pages 134-141

  Yu, Wei Dong ^a   McElwain, Mariann C ^a   Modzelewski, Ruth A ^a   Russell, Derick M ^a   Smith, David C ^a,b   Trump, Donald L ^a   Johnson, Candace S ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; DEXAMETHASONE; GLUCOCORTICOID; TRITIUM; VITAMIN D RECEPTOR;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CALCIUM ABSORPTION; CANCER CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; DRUG EFFECT; GROWTH INHIBITION; HYPERCALCEMIA; LIGAND BINDING; MOUSE; NONHUMAN; RECEPTOR BINDING; SQUAMOUS CELL CARCINOMA; VITAMIN D METABOLISM;

EID: 0032554056     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.2.134     Document Type: Article

References (51)

1. Bikle DD, Pillai S. Vitarain D, calcium, and epidermal differentiation. Endocr Rev 1993;14:3-19.
2. Reichel H, Koeffler HP, Norman AW. The role of the vitamin D endocrine system in health and disease. N Engl J Med 1989;320:980-91.
3. 3 and malignant melanoma: the presence of receptors and inhibition of growth in culture. Endocrinology 1981;108:1083-6.
4. 3 metabolites. Cancer Res 1983;43: 4443-7.
5. 3 analogues and tamoxifen. Cancer Res 1994;54:5711-7.
6. 3 on the morphology of human breast cancer cell line BT.20. Differentiation 1989;40:63-9.
7. 3. Proc Natl Acad Sci U S A 1983;80:5907-11.
8. 3. Proc Natl Acad Sci U S A 1981;78: 4990-4.
9. 3) on head and neck squamous cell carcinoma cell lines. Eur Arch Otorhinolaryngol 1996;253:341-4.
10. Esquenet M, Swinnen JV, Heyns W, Verhoeven G. Control of LNCaP proliferation and differentiation: actions and interactions of androgens 1α,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid and phenylacetate. Prostate 1996;28:182-94.
11. 3 on primary cultures of human prostatic cells. Cancer Res 1994;54:805-10.
12. 3, receptors as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res 1993;53: 3712-8.
13. 3,-induced differentiation in a human promyelocytic leukemia cell line (HL-60): receptor-mediated maturation to macrophage-like cells. J Cell Biol 1984;98:391-8.
14. Colston KW, Berger U, Coombes RC. Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet 1989;28:188-91.
15. 3 prolongs survival time of leukemic mice. Proc Natl Acad Sci U S A 1990;87:3929-32.
16. Albert DM, Marcus DM, Gallo JP, O'Brien JM. The antineoplastic effect of vitamin D in transgenic mice with retinoblastoma. Invest Ophthalmol Vis Sci 1993;33:2354-64.
17. 3 analog in a squamous cell carcinoma model system. Mol Cell Diff 1995;3:31-50.
18. Klein RG, Arnaud SB, Gallagher JC, Deluca HF, Riggs LB. Intestinal calcium absorption in exogenous hypercortisonism. Role of 25-hydroxyvitamin D and corticosteroid dose. J Clin Invest 1977;60:253-9.
19. Suzuki Y, Ichikawa Y, Saito E, Homma M. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 1983;32:151-6.
20. Haynes RC. Agents affecting calcification: calcium, parathyroid hormone, calcitonin, vitamin D, and other compounds. In: Gilman AG, Rall TW, Nies AS, Taylor P, editors. The pharmacological basis of therapeutics. New York: Pergamon Press, 1990;1496-522.
21. Feldman D, McCain TA, Hirst MA, Chen TL, Colston KW. Characterization of a cytoplasmic receptor-like binder for 1α, 25-dihydroxycholecalciferol in rat intestinal mucosa. J Biol Chem 1979;254:10378-84.
22. 3 receptors: divergent effects on mouse and rat intestine. Endocrinology 1982;111:1400-2.
23. 3 receptor levels and augments bioresponses in rat osteoblast-like cells. Endocrinology 1986;118:1119-26.
24. 3 receptors in mouse intestine. Biochem Biophys Res Commun 1982;105:1590-6.
25. Colston K, Colston MJ, Fieldsteel AH, Feldman D. 1,25-Dihydroxyvitamin D receptors in human epithelial cancer cell lines. Cancer Res 1982;42: 856-9.
26. Colston K, Hirt M, Feldman D. Organ distribution of the cytoplasmic 1,25-dihydroxycholecalciferol receptor in various mouse tissues. Endocrinology 1980;107:1916-22.
27. Pike JW, Gooze LL, Haussler MR. Biochemical evidence for 1,25-dihydroxyvitamin D receptor macromolecules in parathyroid, pancreatic, pituitary and placental tissue. Life Sci 1986;26:407-14.
28. 3 receptors and human colon adenocarcinoma. Br J Surg 1991;78:435-9.
29. Magrassi L, Bono F, Milanesi G, Butti G. Vitamin D receptor expression in human brain tumors. J Neurosurg Sci 1993;36:27-30.
30. 3 receptors in human carcinomas: a pilot study. Cancer Res 1991;51: 2021-4.
31. Link R, DeLuca HF. The vitamin D receptor. In: Conn PM, editor. The receptors, vol 2. New York: Academic Press, 1985:1-35.
32. 3 inhibits the clonogenic growth of transformed cells via its receptor. Biochem Biophys Res Commun 1986;139:136-43.
33. Fu KK, Rayner PA, Lam KN. Modification of the effects of continuous low dose rate irradiation by concurrent chemotherapy infusion. Int Radiat Oncol Biol Phys 1984;10:1473-8.
34. Kaufman RA, Tietz NW. Ion effects in measurement of ionized calcium with a calcium-selective electrode. Clin Chem 1980;26:640-4.
35. Chang MJ, Yu WD, Reyno LM, Modzelewski RA, Egorin MJ, Erkmen K, et al. Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model. Cancer Res 1994;54:5380-6.
36. Johnson CS, Chang MJ, Yu WD, Modzelewski RA, Grandis JR, Vlock DR, et al. Synergistic enhancement by interleukin-1 alpha of cisplatin-mediated antitumor activity in RIF-1 tumor-bearing C3H/HeJ mice. Cancer Chemother Pharmacol 1993;32:339-46.
37. Braunschweiger PG, Johnson CS, Kumar N, Ord V, Furmanski P. Antitumor effects of recombinant human interleukin-1 alpha in RIF-1 and Panc02 solid tumors. Cancer Res 1988;48:6011-6.
38. Braunschweiger PG, Jones SA, Johnson CS, Furmanski P. Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1 alpha. Cancer Res 1991;51: 5454-60.
39. 3 receptors. Nuclear/cytosol ratio depends on ionic strength. J Biol Chem 1980;255:6799-805.
40. 3. Nutr Rev 1985;43:161-8.
41. 3 in HL60 cells. Cancer Res 1996;56:264-7.
42. 3 on human T lymphocyte activation and proliferation: a cell cycle analysis. J Immunol 1985;135:2279-86.
43. 3. Cell Proliferation 1994;27:37-46.
44. 3 [published erratum appears in Biochem J 1996;318:1079]. Biochem J 1996; 316:361-71.
45. Norman AW, Roth J, Orci L. The vitamin D endocrine system: steroid metabolism, hormone receptors, and biological response (calcium binding proteins). Endocr Rev 1982;3:331-66.
46. Green S, Chambon P. A superfamily of potentially oncogenic hormone receptors [news]. Nature 1986;324:615-7.
47. Kuiper GG, Brinkmann AO. Steroid hormone receptor phosphorylation: is there a physiological role? Mol Cell Endocrinol 1994;100:103-7.
48. 3 receptors in cultured mouse bone cells. J Biol Chem 1982;257:13564-9.
49. Goldin A, Sandberg JS, Henderson ES, Newman JW, Frei E 3d, Holland JF. The chemotherapy of human and animal acute leukemia. Cancer Chemother Rep 1971;55:309-505.
50. Swain SM. Endocrine therapies of cancer. In: Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy: principles and practice. 2nd ed. Philadelphia: Lippincott-Raven Publishers, 1996:59-108.
51. Light BW, Yu WD, McElwain MC, Russell DM, Trump DL, Johnson CS. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res 1997;57: 3759-64.